company background image
CTMX

CytomX Therapeutics NasdaqGS:CTMX Stock Report

Last Price

US$1.81

Market Cap

US$119.6m

7D

4.0%

1Y

-73.2%

Updated

25 Nov, 2022

Data

Company Financials +
CTMX fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

CTMX Stock Overview

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States.

CytomX Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for CytomX Therapeutics
Historical stock prices
Current Share PriceUS$1.81
52 Week HighUS$6.97
52 Week LowUS$1.17
Beta0.38
1 Month Change33.09%
3 Month Change18.30%
1 Year Change-73.19%
3 Year Change-71.09%
5 Year Change-91.41%
Change since IPO-85.97%

Recent News & Updates

Growth Investors: Industry Analysts Just Upgraded Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Revenue Forecasts By 14%

Nov 10
Growth Investors: Industry Analysts Just Upgraded Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Revenue Forecasts By 14%

Recent updates

Growth Investors: Industry Analysts Just Upgraded Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Revenue Forecasts By 14%

Nov 10
Growth Investors: Industry Analysts Just Upgraded Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Revenue Forecasts By 14%

Here's Why We're Watching CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Situation

Jun 08
Here's Why We're Watching CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Situation

Is CytomX Therapeutics (NASDAQ:CTMX) In A Good Position To Invest In Growth?

Feb 10
Is CytomX Therapeutics (NASDAQ:CTMX) In A Good Position To Invest In Growth?

We're Keeping An Eye On CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Rate

Aug 11
We're Keeping An Eye On CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Rate

Shareholders Will Probably Hold Off On Increasing CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) CEO Compensation For The Time Being

Jun 10
Shareholders Will Probably Hold Off On Increasing CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) CEO Compensation For The Time Being

Growth Investors: Industry Analysts Just Upgraded Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Revenue Forecasts By 11%

Mar 25
Growth Investors: Industry Analysts Just Upgraded Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Revenue Forecasts By 11%

Would Shareholders Who Purchased CytomX Therapeutics' (NASDAQ:CTMX) Stock Three Years Be Happy With The Share price Today?

Feb 02
Would Shareholders Who Purchased CytomX Therapeutics' (NASDAQ:CTMX) Stock Three Years Be Happy With The Share price Today?

How Much Of CytomX Therapeutics, Inc. (NASDAQ:CTMX) Do Institutions Own?

Dec 29
How Much Of CytomX Therapeutics, Inc. (NASDAQ:CTMX) Do Institutions Own?

Here's Why We're Not At All Concerned With CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Situation

Dec 03
Here's Why We're Not At All Concerned With CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Situation

Shareholder Returns

CTMXUS BiotechsUS Market
7D4.0%0.4%1.3%
1Y-73.2%-14.4%-18.5%

Return vs Industry: CTMX underperformed the US Biotechs industry which returned -13.5% over the past year.

Return vs Market: CTMX underperformed the US Market which returned -20.2% over the past year.

Price Volatility

Is CTMX's price volatile compared to industry and market?
CTMX volatility
CTMX Average Weekly Movement12.1%
Biotechs Industry Average Movement11.1%
Market Average Movement7.4%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market3.3%

Stable Share Price: CTMX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: CTMX's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2008176Sean McCarthyhttps://www.cytomx.com

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company’s product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors.

CytomX Therapeutics, Inc. Fundamentals Summary

How do CytomX Therapeutics's earnings and revenue compare to its market cap?
CTMX fundamental statistics
Market CapUS$119.61m
Earnings (TTM)-US$97.59m
Revenue (TTM)US$71.94m

1.7x

P/S Ratio

-1.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CTMX income statement (TTM)
RevenueUS$71.94m
Cost of RevenueUS$0
Gross ProfitUS$71.94m
Other ExpensesUS$169.54m
Earnings-US$97.59m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.48
Gross Margin100.00%
Net Profit Margin-135.65%
Debt/Equity Ratio0%

How did CTMX perform over the long term?

See historical performance and comparison